Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 74-86

  Mallo, Mar ^a,b,c   del Rey, Mónica ^d   Ibáñez, Mariam ^e   Calasanz, Ma José ^f   Arenillas, Leonor ^a   Larráyoz, Ma José ^f   Pedro, Carmen ^a   Jerez, Andrés ^g   Maciejewski, Jaroslaw ^g   Costa, Dolors ^h   Nomdedeu, Meritxell ^h   Diez Campelo, María ^d   Lumbreras, Eva ^d   González Martínez, Teresa ⁱ   Marugán, Isabel ^j   Such, Esperanza ^e   Cervera, José ^e   Cigudosa, Juan C ^k   Álvarez, Sara ^k   Florensa, Lourdes ^a   Hernández, Jesús Ma ^d   Solé, Francesc ^a,b   more..

^a HOSPITAL DEL MAR   (Spain)

^b JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Centro de Investigacion del Cancer   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

^g TAUSSIG CANCER INSTITUTE   (United States)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ Instituto de Salud Carlos III   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k Centro Nacional de Investigaciones Oncológicas   (Spain)

more..

Author keywords

Deletion 5q; Lenalidomide; Myelodysplastic syndrome; Single nucleotide polymorphism array; TP53

Indexed keywords

LENALIDOMIDE;

ADULT; AGED; ARTICLE; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION 5; CHROMOSOME LOSS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CHROMOSOME BANDING; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84879121023     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12354     Document Type: Article

References (56)

1. Bartlett, J.B., Tozer, A., Stirling, D. & Zeldis, J.B. (2005) Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. British Journal of Cancer, 93, 613-619.
2. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine, 364, 2496-2506.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
4. Boultwood, J., Fidler, C., Strickson, A.J., Watkins, F., Gama, S., Kearney, L., Tosi, S., Kasprzyk, A., Cheng, J.F., Jaju, R.J. & Wainscoat, J.S. (2002) Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood, 99, 4638-4641.
5. Brunning, R.D., Bennett, J., Flandrin, G., Matutes, E., Head, D., Vardiman, J.W. & Harris, N.L. (2001) Myelodysplastic syndromes. In: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman), pp. 61-73. IARC, Lyon.
6. Carbuccia, N., Trouplin, V., Gelsi-Boyer, V., Murati, A., Rocquain, J., Adelaide, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., Birnbaum, D. & Mozziconacci, M.J. (2010) Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, 24, 469-473.
7. Chen, C., Bowen, D.T., Giagounidis, A.A., Schlegelberger, B., Haase, S. & Wright, E.G. (2010) Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). Leukemia, 24, 1875-1884.
8. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
9. Christiansen, D.H., Andersen, M.K. & Pedersen-Bjergaard, J. (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology, 19, 1405-1413.
10. Corey, S.J., Minden, M.D., Barber, D.L., Kantarjian, H., Wang, J.C. & Schimmer, A.D. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nature Reviews Cancer, 7, 118-129.
11. Damm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronne, L., Scourzic, L., Chesnais, V., Guerci-Bresler, A., Slama, B., Beyne-Rauzy, O., Schmidt-Tanguy, A., Stamatoullas-Bastard, A., Dreyfus, F., Prebet, T., de Botton, S., Vey, N., Morgan, M.A., Cross, N.C., Preudhomme, C., Birnbaum, D., Bernard, O.A., Fontenay, M. & on behalf of the Groupe Francophone des Myelodysplasies. (2012) Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 119, 3211-3218.
12. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. The New England Journal of Medicine, 360, 2289-2301.
13. Douet-Guilbert, N., De Braekeleer, E., Basinko, A., Herry, A., Gueganic, N., Bovo, C., Trillet, K., Dos Santos, A., Le Bris, M.J., Morel, F., Eveillard, J.R., Berthou, C. & De Braekeleer, M. (2012) Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients. Leukemia, 26, 1695-1697.
14. Ebert, B.L., Galili, N., Tamayo, P., Bosco, J., Mak, R., Pretz, J., Tanguturi, S., Ladd-Acosta, C., Stone, R., Golub, T.R. & Raza, A. (2008a) An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Medicine, 5, e35.
15. Ebert, B.L., Pretz, J., Bosco, J., Chang, C.Y., Tamayo, P., Galili, N., Raza, A., Root, D.E., Attar, E., Ellis, S.R. & Golub, T.R. (2008b) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 451, 335-339.
16. Evers, C., Beier, M., Poelitz, A., Hildebrandt, B., Servan, K., Drechsler, M., Germing, U., Royer, H.D. & Royer-Pokora, B. (2007) Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes, Chromosomes & Cancer, 46, 1119-1128.
17. Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Te Boekhorst, P., Sanz, G., Del Canizo, C., Guerci-Bresler, A., Nilsson, L., Platzbecker, U., Lubbert, M., Quesnel, B., Cazzola, M., Ganser, A., Bowen, D., Schlegelberger, B., Aul, C., Knight, R., Francis, J., Fu, T., Hellstrom-Lindberg, E. & MDS-004 Lenalidomide del5q Study Group. (2011) A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 118, 3765-3776.
18. Feys, T., Poppe, B., De Preter, K., Van Roy, N., Verhasselt, B., De Paepe, P., De Paepe, A. & Speleman, F. (2007) A detailed inventory of DNA copy number alterations in four commonly used hodgkin's lymphoma cell lines. Haematologica, 92, 913-920.
19. Fidler, C., Watkins, F., Bowen, D.T., Littlewood, T.J., Wainscoat, J.S. & Boultwood, J. (2004) NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica, 89, 865-866.
20. Göhring, G., Lange, K., Hofmann, W., Nielsen, K.V., Hellstrom-Lindberg, E., Roy, L., Morgan, M., Kreipe, H., Busche, G., Giagounidis, A. & Schlegelberger, B. (2012) Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia, 26, 356-358.
21. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088. ERRATUM. (1998) Blood, 91, 1100.
22. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
23. Haase, D. (2008) Cytogenetic features in myelodysplastic syndromes. Annals of Hematology, 87, 515-526.
24. Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., Lubbert, M., Kunzmann, R., Giagounidis, A.A., Aul, C., Trumper, L., Krieger, O., Stauder, R., Muller, T.H., Wimazal, F., Valent, P., Fonatsch, C. & Steidl, C. (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 110, 4385-4395.
25. Heinrichs, S., Kulkarni, R.V., Bueso-Ramos, C.E., Levine, R.L., Loh, M.L., Li, C., Neuberg, D., Kornblau, S.M., Issa, J.P., Gilliland, D.G., Garcia-Manero, G., Kantarjian, H.M., Estey, E.H. & Look, A.T. (2009) Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia, 23, 1605-1613.
26. Jädersten, M., Saft, L., Pellagatti, A., Göhring, G., Wainscoat, J.S., Boultwood, J., Porwit, A., Schlegelberger, B. & Hellstrom-Lindberg, E. (2009) Clonal heterogeneity in the 5q- syndrome: P53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 94, 1762-1766.
27. Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellstrom-Lindberg, E. & Mufti, G.J. (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29, 1971-1979.
28. Jerez, A., Gondek, L.P., Jankowska, A.M., Makishima, H., Przychodzen, B., Tiu, R.V., O'Keefe, C.L., Mohamedali, A.M., Batista, D., Sekeres, M.A., McDevitt, M.A., Mufti, G.J. & Maciejewski, J.P. (2012) Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. Journal of Clinical Oncology, 30, 1343-1349.
29. Jonasova, A., Cermak, J., Vondrakova, J., Siskova, M., Hochova, I., Kadlckova, E., Cerna, O., Sykora, M., Vozobulova, V., Seifertova, N., Michalova, K., Zemanova, Z., Brezinova, J., Belohlavkova, P., Kostecka, A. & Neuwirtova, R. (2012) Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and intermediate-1). Leukemia Research, 36, e222-e224.
30. Krypuy, M., Ahmed, A.A., Etemadmoghadam, D., Hyland, S.J., Australian Ovarian Cancer Study Group, DeFazio, A., Fox, S.B., Brenton, J.D., Bowtell, D.D. & Dobrovic, A. (2007) High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer, 7, 168.
31. Krzywinski, M., Schein, J., Birol, I., Connors, J., Gascoyne, R., Horsman, D., Jones, S.J. & Marra, M.A. (2009) Circos: an information aesthetic for comparative genomics. Genome Research, 19, 1639-1645.
32. Kuendgen, A., Lauseker, M., List, A.F., Fenaux, P., Giagounidis, A.A., Brandenburg, N.A., Backstrom, J., Glasmacher, A., Hasford, J. & Germing, U. (2012) Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia, doi: 10.1038/leu.2012.369.
33. Kulasekararaj, AG., Smith, AE., Mian, SA., Mohamedali, AM., Krishnamurthy, P., Lea, NC., Gáken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., Pomplun, S., Marsh, JC., Mufti, G.J. (2013) TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. British Journal of Haematology. 160, 660-672.
34. Le Bras, F., Sebert, M., Kelaidi, C., Lamy, T., Dreyfus, F., Delaunay, J., Banos, A., Blanc, M., Vey, N., Schmidt, A., Visanica, S., Eclache, V., Turlure, P., Beyne-Rauzy, O., Guerci, A., Delmer, A., de Botton, S., Rea, D., Fenaux, P. & Ades, L. (2011) Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-the GFM experience. Leukemia Research, 35, 1444-1448.
35. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J. & Knight, R. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine, 355, 1456-1465.
36. Maciejewski, J.P., Tiu, R.V. & O'Keefe, C. (2009) Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. British Journal of Haematology, 146, 479-488.
37. Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R.L., Kojima, S., List, A.F., Sekeres, M.A., McDevitt, M.A. & Maciejewski, J.P. (2009) Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of Clinical Oncology, 27, 6109-6116.
38. Mallo, M., Cervera, J., Schanz, J., Such, E., Garcia-Manero, G., Luno, E., Steidl, C., Espinet, B., Vallespi, T., Germing, U., Blum, S., Ohyashiki, K., Grau, J., Pfeilstocker, M., Hernandez, J.M., Noesslinger, T., Giagounidis, A., Aul, C., Calasanz, M.J., Martin, M.L., Valent, P., Collado, R., Haferlach, C., Fonatsch, C., Lubbert, M., Stauder, R., Hildebrandt, B., Krieger, O., Pedro, C., Arenillas, L., Sanz, M.A., Valencia, A., Florensa, L., Sanz, G.F., Haase, D. & Sole, F. (2011) Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia, 25, 110-120.
39. Mohamedali, A., Gaken, J., Twine, N.A., Ingram, W., Westwood, N., Lea, N.C., Hayden, J., Donaldson, N., Aul, C., Gattermann, N., Giagounidis, A., Germing, U., List, A.F. & Mufti, G.J. (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood, 110, 3365-3373.
40. Oliva, E.N., Cuzzola, M., Aloe Spiriti, M.A., Poloni, A., Lagana, C., Rigolino, C., Morabito, F., Galimberti, S., Ghio, R., Cortelezzi, A., Palumbo, G.A., Sanpaolo, G., Finelli, C., Ricco, A., Volpe, A., Roda, F., Breccia, M., Alimena, G., Nobile, F. & Latagliata, R. (2012) Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Annals of Hematology, 92, 25-32.
41. Pardanani, A., Patnaik, M.M., Lasho, T.L., Mai, M., Knudson, R.A., Finke, C., Ketterling, R.P., McClure, R.F. & Tefferi, A. (2010) Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia, 24, 1370-1372.
42. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
43. Patnaik, M.M., Lasho, T.L., Finke, C.M., Gangat, N., Caramazza, D., Holtan, S.G., Pardanani, A., Knudson, R.A., Ketterling, R.P., Chen, D., Hoyer, J.D., Hanson, C.A. & Tefferi, A. (2010) WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia, 24, 1283-1289.
44. Patnaik, M.M., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R.P., Chen, D., Hoyer, J.D., Hanson, C.A. & Tefferi, A. (2011) Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. American Journal of Hematology, 86, 393-398.
45. Sebaa, A., Ades, L., Baran-Marzack, F., Mozziconacci, M.J., Penther, D., Dobbelstein, S., Stamatoullas, A., Recher, C., Prebet, T., Moulessehoul, S., Fenaux, P. & Eclache, V. (2012) Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes, Chromosomes & Cancer, 51, 1086-1092.
46. Sekeres, M.A., Maciejewski, J.P., Giagounidis, A.A., Wride, K., Knight, R., Raza, A. & List, A.F. (2008) Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology, 26, 5943-5949.
47. Sekeres, M., Giagounidis, A., List, A., Sanz, G., Selleslag, D., Backstrom, J., Fu, T. & Fenaux, P. (2011) Predictive factors for overall survival (OS) and AML progression in a large cohort of patients with low-/Int-1-risk MDS with del(5q) treated with lenalidomide (LEN). Haematologica, 96, 202, abstract 481
48. Shaffer, L., Slovak, M. & Campbell, L. (2009) ISCN2009: An International System for Human Cytogenetic Nomenclature. Karger AG, Basel, Switzerland.
49. Solé, F., Luño, E., Sanzo, C., Espinet, B., Sanz, G.F., Cervera, J., Calasanz, M.J., Cigudosa, J.C., Milla, F., Ribera, J.M., Bureo, E., Márquez, M.L., Arranz, E. & Florensa, L. (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 90, 1168-1178.
50. Starczynowski, D.T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R.A., Buckstein, R., Lam, W., Humphries, R.K. & Karsan, A. (2010) Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine, 16, 49-58.
51. Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Elson, P., Huh, J., Mohamedali, A., Kulasekararaj, A., Advani, A.S., Paquette, R., List, A.F., Sekeres, M.A., McDevitt, M.A., Mufti, G.J. & Maciejewski, J.P. (2011) Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood, 117, 4552-4560.
52. Venner, C.P., Wegrzyn Woltosz, J., Nevill, T.J., Deeg, H.J., Caceres, G., Platzbecker, U., Scott, B.L., Sokol, L., Sung, S., List, A.F. & Karsan, A. (2012) Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome. Haematologica, 98, 409-413.
53. Villa, O., Del Campo, M., Salido, M., Gener, B., Astier, L., Del Valle, J., Gallastegui, F., Perez-Jurado, L.A. & Sole, F. (2007) Small supernumerary marker chromosome causing partial trisomy 6p in a child with craniosynostosis. American Journal of Medical Genetics, 143A, 1108-1113.
54. Wagner, K., Damm, F., Göhring, G., Gorlich, K., Heuser, M., Schafer, I., Ottmann, O., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A.A., Fiedler, W., Kirchner, H.H., Brugger, W., Zucknick, M., Schlegelberger, B., Heil, G., Ganser, A. & Krauter, J. (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Journal of Clinical Oncology, 28, 2356-2364.
55. Wang, L., Fidler, C., Nadig, N., Giagounidis, A., Della Porta, M.G., Malcovati, L., Killick, S., Gattermann, N., Aul, C., Boultwood, J. & Wainscoat, J.S. (2008) Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica, 93, 994-1000.
56. Wei, S., Chen, X., McGraw, K., Zhang, L., Komrokji, R., Clark, J., Caceres, G., Billingsley, D., Sokol, L., Lancet, J., Fortenbery, N., Zhou, J., Eksioglu, E.A., Sallman, D., Wang, H., Epling-Burnette, P.K., Djeu, J., Sekeres, M., Maciejewski, J.P. & List, A. (2013) Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene, 32, 1110-1120.